Auven Therapeutics Management LLLP, of St. Thomas, U.S. Virgin Islands, said it executed agreements to sell 100 percent of Ocular Technologies Sarl, a wholly owned subsidiary through which all rights to Seciera (OTX-101) are held, to a subsidiary of Sun Pharmaceuticals Industries Ltd., of Mumbai, India.